NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator.
The first patient has been randomized in a Phase II clinical trial which is evaluating NBI-1070770 in adults with major depressive disorder, according to a press release.1 Neurocrine Biosciences’ NBI-1070770 is a novel, selective, and orally active, negative allosteric modulator (NAM) of the NR2B subunit-containing N-methyl-D-aspartate (NMDA NR2B) receptor.
The Phase II trial (NCT06267846) is multi-center, randomized, double-blind, placebo-controlled study that will enroll approximately 72 adults and is being conducted at centers throughout the United States. It will evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to a placebo on improving symptoms of depression based on measurements by the Montgomery-Åsberg Depression Rating Scale.
The study is estimated to be completed in December 2025, with a primary completion in September 2025.
According to the National Institute of Mental Health, major depression is one of the most common mental disorders in the United States. Among US adults aged 18 or older in 2021, an estimated 21.0 million had at least one major depressive episode. This number represented 8.3% of all US adults.2
"Based upon our Phase I first-in-human study, we are excited to bring this novel oral compound, which acts through a clinically validated mechanism of action, into clinical development as a potential treatment for major depressive disorder," Eiry W. Roberts, MD, chief medical officer of Neurocrine Biosciences said in the press release. "The selectivity of NBI-1070770 for the NMDA NR2B receptor has the potential to benefit patients who have moderate to severe depression."
1. Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder. News release. April 3, 2024. Accessed April 5, 2024. https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-first-patient-dosed-in-phase-2-clinical-study-evaluating-nbi-1070770-in-adults-with-major-depressive-disorder-302106187.html
2. Major Depression. National Institute of Mental Health. Updated July 2023. Accessed April 5, 2024. https://www.nimh.nih.gov/health/statistics/major-depression
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.